Equities research analysts expect Illumina, Inc. (NASDAQ:ILMN) to post sales of $786.19 million for the current fiscal quarter, according to Zacks. Seven analysts have made estimates for Illumina’s earnings, with the lowest sales estimate coming in at $775.00 million and the highest estimate coming in at $796.93 million. Illumina posted sales of $662.00 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.8%. The business is expected to report its next quarterly earnings report on Tuesday, August 7th.
According to Zacks, analysts expect that Illumina will report full year sales of $3.20 billion for the current year, with estimates ranging from $3.17 billion to $3.25 billion. For the next fiscal year, analysts expect that the company will report sales of $3.57 billion per share, with estimates ranging from $3.45 billion to $3.78 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.02 by $0.43. The firm had revenue of $782.00 million for the quarter, compared to the consensus estimate of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The business’s revenue was up 30.8% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share.
Several research analysts have commented on ILMN shares. Morgan Stanley lifted their price target on shares of Illumina from $157.00 to $170.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 11th. Barclays raised shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 price target on the stock in a research note on Monday, May 7th. BTIG Research reissued a “hold” rating on shares of Illumina in a research note on Wednesday, April 25th. Robert W. Baird lifted their price target on shares of Illumina from $261.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 25th. Finally, ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $256.42.
Illumina opened at $280.77 on Thursday, Marketbeat.com reports. The company has a market cap of $41.02 billion, a price-to-earnings ratio of 70.19, a price-to-earnings-growth ratio of 2.98 and a beta of 0.90. Illumina has a one year low of $167.98 and a one year high of $293.15. The company has a current ratio of 2.71, a quick ratio of 2.41 and a debt-to-equity ratio of 0.23.
In related news, SVP Oene Mark Van sold 1,400 shares of Illumina stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $238.48, for a total value of $333,872.00. Following the sale, the senior vice president now owns 12,217 shares in the company, valued at $2,913,510.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director A Blaine Bowman sold 3,000 shares of Illumina stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $241.45, for a total transaction of $724,350.00. Following the completion of the sale, the director now owns 18,668 shares in the company, valued at approximately $4,507,388.60. The disclosure for this sale can be found here. Insiders sold 38,255 shares of company stock worth $10,346,221 in the last 90 days. Company insiders own 0.54% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. Captrust Financial Advisors bought a new stake in Illumina in the fourth quarter valued at $165,000. MetLife Investment Advisors LLC bought a new stake in Illumina in the fourth quarter valued at $9,870,000. Xact Kapitalforvaltning AB boosted its holdings in Illumina by 10.4% in the fourth quarter. Xact Kapitalforvaltning AB now owns 25,667 shares of the life sciences company’s stock valued at $5,608,000 after acquiring an additional 2,425 shares in the last quarter. Stone Ridge Asset Management LLC bought a new stake in Illumina in the fourth quarter valued at $306,000. Finally, Prudential Financial Inc. boosted its holdings in Illumina by 75.9% in the first quarter. Prudential Financial Inc. now owns 762,186 shares of the life sciences company’s stock valued at $180,196,000 after acquiring an additional 328,886 shares in the last quarter. Institutional investors and hedge funds own 90.54% of the company’s stock.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Get a free copy of the Zacks research report on Illumina (ILMN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.